8-K: Avalon GloboCare Receives Patent Allowance in China for CAR-T and CAR-NK Cell Technology

Avalon GloboCare has secured a Notice of Allowance from China for its AVAR1901CN patent, enhancing its global intellectual property portfolio in CAR-T and CAR-NK cell therapies.

Summary

• Avalon GloboCare Corp. has received a Notice of Allowance from the China National Intellectual Property Administration (CNIPA) for its patent application AVAR1901CN.
• The patent, co-developed with Hong Kong-based Arbele Limited, focuses on enhancing the expansion, manufacturing, survival, and efficacy of CAR-T and CAR-Natural Killer (NK) cells.
• The AVAR1901CN patent includes a bispecific anti-CD19xCD22 CAR design to minimize tumor escape and localized cytokine induction to improve CAR cell cytotoxicity and stimulate a host anti-tumor immune response.
• Avalon's CEO, David Jin, believes this technology will provide cost-effective solutions for point-of-care cancer treatment and improve patient outcomes worldwide.
• The company is dedicated to developing and delivering innovative, transformative, precision diagnostics and clinical laboratory services.

Sentiment

Score: 7

Explanation: The announcement is positive due to the patent allowance in China, which strengthens the company's intellectual property and market position. However, it's important to consider the risks associated with forward-looking statements and the competitive landscape.

Positives

• The patent allowance expands Avalon's global intellectual property footprint to China.
• The technology targets both CD19 and CD22 antigens, reducing the risk of tumor escape.
• Localized cytokine induction enhances CAR cell cytotoxicity and stimulates a host anti-tumor immune response.
• The company believes its innovations will improve accessibility and lead to better outcomes for patients worldwide.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Actual results may differ materially from those indicated by forward-looking statements due to various factors disclosed in the company's filings with the SEC, including general industry and market conditions, economic conditions, and governmental and public policy changes.

Future Outlook

The company aims to provide practical, cost-effective, and efficient solutions for point-of-care cancer treatment and improve accessibility and lead to better outcomes for patients worldwide.

Management Comments

• David Jin, M.D., Ph.D., Avalon's CEO, stated that the bispecific anti-CD19xCD22 CAR is designed to target both CD19 and CD22 antigens, effectively reducing the risk of tumor escape due to antigen loss.
• He also mentioned that the innovative approach induces a localized cytokine response, ensuring cytokines are activated only upon tumor cell engagement, enhancing CAR cell cytotoxicity, survival, and proliferation while stimulating a host anti-tumor immune response.
• Jin believes that advancing this groundbreaking platform technology will provide practical, cost-effective, and efficient solutions for point-of-care cancer treatment and that expanding their intellectual property into China further solidifies their leadership in cell-based immunotherapy.

Industry Context

The announcement positions Avalon GloboCare in the competitive cell-based immunotherapy market, particularly in CAR-T and CAR-NK cell therapies, with a focus on expanding its intellectual property and market presence in China.

Comparison to Industry Standards

• The bispecific CAR-T approach targeting both CD19 and CD22 is a strategy employed by companies like Novartis and Kite Pharma (Gilead) to address antigen escape, a common resistance mechanism in CAR-T therapy.
• Localized cytokine induction is a method to improve CAR-T cell safety and efficacy, similar to approaches being developed by companies like Cellectis and Precision BioSciences to control cytokine release syndrome (CRS) and neurotoxicity.
• Expanding into China is a strategic move, as the Chinese market represents a significant growth opportunity for cell therapies, with companies like Legend Biotech and CARsgen Therapeutics already having established a presence there.

Stakeholder Impact

• Shareholders may react positively to the news of the patent allowance.
• The development could lead to improved treatment options for cancer patients.
• The company's employees may benefit from the company's growth and expansion.

Key Dates

Keywords

CAR-T, CAR-NK, Patent, Immunotherapy, China, Avalon GloboCare, AVAR1901CN, Biotech, Cancer Treatment